Phosphoglycerate kinase 1 as a Potential Biomarker and Therapeutic Target for Diabetic Sarcopenia.

IF 6.4 4区医学 Q1 MEDICINE, GENERAL & INTERNAL

QJM: An International Journal of Medicine Pub Date : 2025-09-16 DOI:10.1093/qjmed/hcaf212

Fangyu Li, Qingsheng Wang, Rui Li, Yuanyuan Gao, Ying Wang, Qi Chen

{"title":"Phosphoglycerate kinase 1 as a Potential Biomarker and Therapeutic Target for Diabetic Sarcopenia.","authors":"Fangyu Li, Qingsheng Wang, Rui Li, Yuanyuan Gao, Ying Wang, Qi Chen","doi":"10.1093/qjmed/hcaf212","DOIUrl":null,"url":null,"abstract":"Background: Sarcopenia is a novel complication of type 2 diabetes mellitus (T2DM), the incidence of which is rapidly increasing. Therefore, early detection and diagnosis of diabetic sarcopenia is important to improve the quality of life of patients.Methods: Differentially expressed genes (DEGs) were identified from GEO datasets GSE76895 and GSE1428. GO and KEGG pathway analyses were conducted using DAVID and KOBAS. Hub gene of metabolic pathways were validated using gene expression and ROC curves. Hub gene expression was then validated in mouse models and human populations, and therapeutic potential was assessed.Results: The metabolic pathway is an important pathophysiological feature of T2DM and sarcopenia, with 17 genes co-enriched in this pathway. We focused on the PGK1, stained by immunofluorescence and western blot analysis revealed significantly lower expression of PGK1 in pancreatic islets and skeletal muscles of T2DM mice, with a negative correlation with the diabetic cycle. Similarly, serum levels of PGK1 were lower in T2DM patients than in healthy individuals. Overexpression of PGK1 alleviates metabolic stress and improves skeletal muscle function in diabetic sarcopenia, highlighting its potential as a therapeutic target.Conclusion: These results suggest that PGK1 may serve as a novel biomarker and potential target for diabetic sarcopenia.","PeriodicalId":20806,"journal":{"name":"QJM: An International Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":6.4000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"QJM: An International Journal of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/qjmed/hcaf212","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Sarcopenia is a novel complication of type 2 diabetes mellitus (T2DM), the incidence of which is rapidly increasing. Therefore, early detection and diagnosis of diabetic sarcopenia is important to improve the quality of life of patients.

Methods: Differentially expressed genes (DEGs) were identified from GEO datasets GSE76895 and GSE1428. GO and KEGG pathway analyses were conducted using DAVID and KOBAS. Hub gene of metabolic pathways were validated using gene expression and ROC curves. Hub gene expression was then validated in mouse models and human populations, and therapeutic potential was assessed.

Results: The metabolic pathway is an important pathophysiological feature of T2DM and sarcopenia, with 17 genes co-enriched in this pathway. We focused on the PGK1, stained by immunofluorescence and western blot analysis revealed significantly lower expression of PGK1 in pancreatic islets and skeletal muscles of T2DM mice, with a negative correlation with the diabetic cycle. Similarly, serum levels of PGK1 were lower in T2DM patients than in healthy individuals. Overexpression of PGK1 alleviates metabolic stress and improves skeletal muscle function in diabetic sarcopenia, highlighting its potential as a therapeutic target.

Conclusion: These results suggest that PGK1 may serve as a novel biomarker and potential target for diabetic sarcopenia.

查看原文本刊更多论文

磷酸甘油酸激酶1作为糖尿病肌少症的潜在生物标志物和治疗靶点。

背景：肌肉减少症是2型糖尿病（T2DM）的一种新型并发症，其发病率正在迅速上升。因此，早期发现和诊断糖尿病性肌肉减少症对提高患者的生活质量具有重要意义。方法：从GEO数据集GSE76895和GSE1428中鉴定差异表达基因（DEGs）。使用DAVID和KOBAS进行GO和KEGG通路分析。通过基因表达和ROC曲线对代谢途径枢纽基因进行验证。然后在小鼠模型和人类群体中验证Hub基因表达，并评估治疗潜力。结果：代谢途径是T2DM和肌肉减少症的重要病理生理特征，该途径共富集了17个基因。我们重点研究了PGK1，通过免疫荧光染色和western blot分析发现，PGK1在T2DM小鼠胰岛和骨骼肌中的表达显著降低，与糖尿病周期呈负相关。同样，T2DM患者的血清PGK1水平低于健康人。PGK1过表达可缓解糖尿病骨骼肌减少症的代谢应激，改善骨骼肌功能，凸显其作为治疗靶点的潜力。结论：这些结果提示PGK1可能作为糖尿病肌少症的一种新的生物标志物和潜在靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

QJM: An International Journal of Medicine 医学-医学：内科

CiteScore

6.90

自引率

5.30%

发文量

263

审稿时长

4-8 weeks

期刊介绍： QJM, a renowned and reputable general medical journal, has been a prominent source of knowledge in the field of internal medicine. With a steadfast commitment to advancing medical science and practice, it features a selection of rigorously reviewed articles. Released on a monthly basis, QJM encompasses a wide range of article types. These include original papers that contribute innovative research, editorials that offer expert opinions, and reviews that provide comprehensive analyses of specific topics. The journal also presents commentary papers aimed at initiating discussions on controversial subjects and allocates a dedicated section for reader correspondence. In summary, QJM's reputable standing stems from its enduring presence in the medical community, consistent publication schedule, and diverse range of content designed to inform and engage readers.